We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Single Test Detects All Existing Strains of H5N1

By LabMedica International staff writers
Posted on 06 Jun 2012
A bird flu diagnostic kit was successfully developed by scientists at a research institute and a hospital in Singapore.

The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.

The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.

The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.

Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.

The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.

"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.

Related Links:

Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Channels

Molecular Diagnostics

view channel
Image: Guardant Health has introduced new applications for Guardant360 Liquid, expanding the test’s capabilities for treatment selection in breast and lung cancers. (Photo courtesy of Guardant Health)

Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations

Treatment selection in advanced breast and lung cancers can be challenging when traditional biomarkers are absent and genomic findings alone do not fully clarify which therapies may be effective.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The collaboration aims to expand access to the technology through a regulated clinical diagnostics pathway in Japan.

Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan

Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more